Literature DB >> 11291878

Macroscopic typing with wall stricture sign may reflect tumor behaviors of advanced colorectal cancers.

S Miyamoto1, N Boku, T Fujii, A Ohtsu, S Matsumoto, H Tajiri, S Yoshida, T Arai, M Ono, T Hasebe, A Ochiai.   

Abstract

No appropriate macroscopic classification of advanced colorectal cancers (A-CRC) is available for assessing their tumor behavior. In the present study, A-CRC were classified macroscopically as either stricture or nonstricture type, and the differences in clinicopathological features, mode of recurrence, and prognosis between the two types were investigated. The subjects were 166 patients with A-CRC invading beyond the muscular layer who had undergone curative surgical resection. Fresh resected specimens from these patients were used for the study. The A-CRC were classified as of stricture or nonstricture type according to whether or not they showed marked fold convergence and/or stricture of the intestinal tract (more than 30% wall shrinkage) that had the appearance of a "bow tie". Of the 166 A-CRC, 47 (28%) were classified as stricture type. This type was significantly more frequent in the colon (37%; 37/101) than in the rectum (15%; 10/65) (P = 0.003). The stricture type was more frequently associated with an abundance of fibrosis than the nonstricture type (76%; 28/37 vs 39%; 25/64 in colon; P < 0.001; 100%, 10/10 vs 42%, 23/55 in rectum; P < 0.001). The recurrence rate was also higher in the stricture type than in the non-stricture type in both the colon (51%, 19/37 vs 17%, 11/64; P = 0.003) and rectum (80%, 8/10 vs 38%, 21/55; P = 0.01). The time to recurrence was significantly shorter for the stricture type in both the colon (P < 0.001) and rectum (P = 0.02). These results indicate that the macroscopic typing of A-CRC according to the presence or absence of wall stricture sign may reflect their tumor behavior, although this behavior appears to be complex and related to tumor progression. This classification could be important clinically to assess tumor behavior in a simple way.

Entities:  

Mesh:

Year:  2001        PMID: 11291878     DOI: 10.1007/s005350170123

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  5 in total

1.  Morphology as a risk factor for the malignant potential of T2 colorectal cancer.

Authors:  Yuichi Mori; Shin-Ei Kudo; Shungo Endo; Chiyo Maeda; Shumpei Mukai; Yasuharu Maeda; Shinichi Kataoka; Kenichi Takeda; Katsuro Ichimasa; Hideyuki Miyachi; Naruhiko Sawada; Eiji Hidaka; Fumio Ishida
Journal:  Mol Clin Oncol       Date:  2016-07-07

2.  Spread of tumor microenvironment contributes to colonic obstruction through subperitoneal fibroblast activation in colon cancer.

Authors:  Mitsuru Yokota; Motohiro Kojima; Youichi Higuchi; Yuji Nishizawa; Akihiro Kobayashi; Masaaki Ito; Norio Saito; Atsushi Ochiai
Journal:  Cancer Sci       Date:  2015-03-19       Impact factor: 6.716

3.  Determining the difference in the efficacy and safety of self-expandable metallic stents as a bridge to surgery for obstructive colon cancer among patients in the CROSS 0 group and those in the CROSS 1 or 2 group: a pooled analysis of data from two Japanese prospective multicenter trials.

Authors:  Takeshi Ohki; Shuntaro Yoshida; Masakazu Yamamoto; Hiroyuki Isayama; Tomonori Yamada; Takeaki Matsuzawa; Shuji Saito; Toshio Kuwai; Masafumi Tomita; Toshiyasu Shiratori; Mamoru Shimada; Tomio Hirakawa; Koichi Koizumi; Yoshihisa Saida
Journal:  Surg Today       Date:  2020-02-06       Impact factor: 2.549

4.  Elastic laminal invasion in colon cancer: diagnostic utility and histological features.

Authors:  Motohiro Kojima; Mitsuru Yokota; Norio Saito; Shogo Nomura; Atsushi Ochiai
Journal:  Front Oncol       Date:  2012-12-11       Impact factor: 6.244

5.  Nomograms predicting survival and recurrence in colonic cancer in the era of complete mesocolic excision.

Authors:  Y Kanemitsu; D Shida; S Tsukamoto; H Ueno; M Ishiguro; S Ishihara; K Komori; K Sugihara
Journal:  BJS Open       Date:  2019-04-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.